Cherelle Lane-Cooper, DO
Internal Medicine · Baltimore, MDNPI 1841486727
Payments from drug & device makers
Across 140 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$458
- Lilly USA, LLC$333
- Boehringer Ingelheim$262
- Amarin Pharma, Inc.$259
- Sanofi-aventis U.S. LLC$237
- Johnson & Johnson$103
- plus $717 from 17 others
What the payments were for
- Food & beverage$2,35199%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $458 |
| Lilly USA, LLC | 20 | $333 |
| Boehringer Ingelheim | 13 | $262 |
| Amarin Pharma, Inc. | 12 | $259 |
| Sanofi-aventis U.S. LLC | 12 | $237 |
| Johnson & Johnson | 4 | $103 |
| Novartis | 5 | $100 |
| AstraZeneca | 5 | $88 |
| Merck | 5 | $74 |
| Amgen | 4 | $69 |
| GSK | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Hikma Pharmaceuticals USA | 3 | $44 |
| AbbVie | 3 | $43 |
| Dexcom, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 1 | $26 |
| Orexo US, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Phadia US Inc. | 1 | $12 |
How this compares
$2,370 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $9,094 |
| Gabapentin | 58 | $994 |
| Pregabalin | 14 | $771 |
| Atorvastatin Calcium | 39 | $500 |
| Aripiprazole | 13 | $414 |
| Furosemide | 32 | $391 |
| Levothyroxine Sodium | 28 | $336 |
| Amlodipine Besylate | 29 | $281 |
| Lisinopril | 20 | $280 |
| Paroxetine Hcl | 16 | $236 |
| Famotidine | 11 | $193 |
| Benztropine Mesylate | 18 | $163 |
| Donepezil Hcl | 11 | $162 |
| Losartan Potassium | 15 | $137 |
| Tramadol Hcl | 12 | $135 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Baltimore
- Kristen MarroneBaltimore$5.6M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Mark YarchoanBaltimore$2.4M
- Gabrielle PrinceBaltimore$2.1M
- Jessica TaoBaltimore$1.2M
- Ana-Maria OrbaiBaltimore$1.1M
- Julie PaikBaltimore$1M
- Christopher MelaniBaltimore$997K
- Ethel WeldBaltimore$792K
- Christian GockeBaltimore$725K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.